18
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1938 |
FLT3-IN-2
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
FLT3-IN-2 是 FLT3 抑制剂(IC50<1 μM)。 | |||
T9856 |
FLT3-IN-10
2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl- |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
FLT3-IN-10 (2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-) (compound 7c) 是有效的 FMS 样酪氨酸激酶 3 (FLT3) 抑制剂。FLT3-IN-10 具有治疗 FLT3 突变的急性髓性白血病 (AML) 的潜力。 | |||
T11707 | JAK2/FLT3-IN-1 | JNK | MAPK |
JAK2/FLT3-IN-1 has anti-cancer activity. JAK2/FLT3-IN-1 is a potent and orally effective dual JAK2/FLT3 (Janus kinase 2/ FMS-like tyrosine kinase 3) inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | |||
T63274 |
FLT3/ITD-IN-2
|
||
FLT3/ITD-IN-2 是 FLT3-ITD 的有效抑制剂,能够作用于 FLT3D835Y (IC50: 0.3 nM)、FLT3(IC50: 0.4 nM)和 FLT3-ITD(IC50: 1.0 nM)。FLT3/ITD-IN-2 能够有效的抑制 FLT3 的磷酸化,能够有效的抑制急性髓系白血病细胞的增殖。 | |||
T63629 | PDGFRα/FLT3-ITD-IN-2 | ||
PDGFRα/FLT3-ITD-IN-2 是 PDGFRα (IC50>20 μM) 和 FLT3 (IC50: 0.004 μM) 的有效抑制剂。PDGFRα/FLT3-ITD-IN-2 对急性髓系白血病或慢性嗜酸性粒细胞白血病表现出研究潜力。 | |||
T9017 |
HPK1-IN-2
Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2,HPK1-IN-2 |
Others; FLT; Src | Angiogenesis; Others; Tyrosine Kinase/Adaptors |
HPK1-IN-2 (Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2) 是一种有效且具有口服活性的造血祖细胞激酶-1 抑制剂(HPK1;IC50<0.05 µM)。它还抑制 Lck (0.05 µM<IC50<0.5 µM) 和 Flt3 (IC50<0.05 µM) 激酶活性,具有抗肿瘤活性。 | |||
T3211 |
Midostaurin
米哚妥林,N-Benzoylstaurosporine,PKC412,CGP41231,CGP 41251,苯甲酰基十字孢碱 |
Others; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; Others |
Midostaurin (PKC412) 是一种多靶点蛋白激酶抑制剂,有抗肿瘤活性,对 PKCα/β/γ、Syk、Flk-1、Akt、PKA、c-Kit、c-Fgr、c-Src、FLT3、PDFRβ和VEGFR1/2的IC50值范围为 22 到500 nM 之间。 | |||
T35900 |
JAK2-IN-7
JAK2-IN-7 |
JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
JAK2-IN-7 是一种选择性 JAK2抑制剂,对 JAK2,SET-2 和 Ba/F3V617F 细胞的IC50为 3、11.7 和 41 nM。 JAK2-IN-7 的选择性是 JAK1, JAK3,FLT3 的 14 倍以上。JAK2-IN-7 刺激细胞周期停滞在 G0/G1 期,并诱导肿瘤细胞凋亡 (apoptosis),具有抗肿瘤活性。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
T81421 |
Pomalidomide-C5-Dovitinib
|
PROTACs | PROTAC |
Pomalidomide-C5-Dovitinib(compound 2)是链接Pomalidomide与Dovitinib的PROTAC,且与CRBN结合。该化合物在FLT3-ITD+ AML细胞中表现出增强的抗增殖能力,通过泛素-蛋白酶体依赖性途径促进FLT3-ITD和KIT蛋白的降解,并彻底抑制其下游信号传导,显示出研究FLT3-ITD+急性髓系白血病的潜力。 | |||
T60760 |
HDAC10-IN-2
|
||
HDAC10-IN-2 (化合物 10c) 调节侵袭性 FLT3-ITD 阳性急性髓系白血病细胞的自噬。HDAC10-IN-2是HDAC10的高选择性抑制剂 (IC50 = 20 nM)。 | |||
T78145 |
HDAC10-IN-2 hydrochloride
|
Autophagy | Autophagy |
HDAC10-IN-2 hydrochloride(化合物10c)是一种对HDAC10具有高效性和高选择性的抑制剂,IC50值为20 nM。该化合物能够调控FLT3-ITD阳性急性髓系白血病细胞的自噬过程。 | |||
T37085 |
Luxeptinib
|
||
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4]. | |||
T61755 |
E6201
|
||
E6201 (ER-806201) is a potent dual kinase inhibitor targeting MEK1 and FLT3, inhibiting their activities in an ATP-competitive manner. It effectively suppresses MEK1-induced ERK2 phosphorylation (IC50 = 5.2 nM), MKK4-induced JNK phosphorylation (IC50 = 91 nM), and MKK6-induced p38 MAPK phosphorylation (IC50 = 19 nM). E6201 exhibits anti-tumor and anti-psoriasis effects [1] [2]. | |||
T29062 |
UNC3133
UNC 3133,UNC-3133 |
||
UNC3133 is a potent and selective Mer tyrosine kinase (MerTK) inhibitor with IC50 Mer 3.0 nM; Axl 17nM; Tyro 3.31 nM; FLT3 6.6 nM; PO Cmax = 0.023; IV T1/2 = 1.59 h, %F = 16. Mer tyrosine kinase (MerTK) is aberrantly elevated in various tumor cells and ha | |||
T62417 |
MELK-8a
|
||
MELK-8a (NVS-MELK8a) 是一种高效的、选择性的母体胚胎亮氨酸拉链激酶 (MELK) 抑制剂 (IC50: 2 nM)。MELK-8a 也能够抑制 Flt3 (ITD) (IC50: 0.18 μM)、Haspin (IC50: 0.19 μM)、PDGFRα (IC50: 0.42 μM)。其中 MELK 在调节癌细胞的细胞有丝分裂中具有重要作用。 | |||
T68389 | LY2457546 | ||
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 synge... | |||
T71382 |
KRC-108
|
||
KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. KRC-108 was also effective for the inhibition of tumo... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6S0033 |
Crotonoside
巴豆苷;异鸟苷,巴豆苷,Isoguanosine,2-HYDROXYADENOSINE |
Others; FLT; HDAC | Angiogenesis; Chromatin/Epigenetic; DNA Damage/DNA Repair; Others; Tyrosine Kinase/Adaptors |
Crotonoside (Isoguanosine) 是从中草药巴豆中分离出来的一种天然产物。 它抑制 FLT3 和 HDAC3/6,有治疗急性髓性白血病 (AML)的研究潜力。 |